|
Name |
alpha-Muurolene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(1S,4aS,8aR)-4,7-dimethyl-1-propan-2-yl-1,2,4a,5,6,8a-hexahydronaphthalene
|
|
SMILES |
CC1=C[C@@H]2[C@H](CC1)C(=CC[C@H]2C(C)C)C
|
|
InChI |
InChI=1S/C15H24/c1-10(2)13-8-6-12(4)14-7-5-11(3)9-15(13)14/h6,9-10,13-15H,5,7-8H2,1-4H3/t13-,14+,15-/m0/s1
|
|
InChIKey |
QMAYBMKBYCGXDH-ZNMIVQPWSA-N
|
|
Synonyms |
alpha-Muurolene; Muurolene; 10208-80-7; B1-Cadinene; D2ZGB75M36; (+)-alpha-muurolene; (1S,4aS,8aR)-4,7-dimethyl-1-(propan-2-yl)-1,2,4a,5,6,8a-hexahydronaphthalene; .alpha.-Muurolene; (1S,4aS,8aR)-1-isopropyl-4,7-dimethyl-1,2,4a,5,6,8a-hexahydronaphthalene; (-)-.alpha.-Muurolene; .alpha.-Muurolene, (-)-; Naphthalene, 1,2,4a,5,6,8a-hexahydro-4,7-dimethyl-1-(1-methylethyl)-, (1S,4aS,8aR)-; (-)-alpha-muurolene; alpha-Muurolene, (-)-; UNII-D2ZGB75M36; CHEBI:64797; DTXSID90144629; NAPHTHALENE, 1,2,4A,5,6,8A-HEXAHYDRO-4,7-DIMETHYL-1-(1-METHYLETHYL)-, (1S-(1.ALPHA.,4A.ALPHA.,8A.ALPHA.))-; 1.BETA.-CADINA-4,9-DIENE; Naphthalene, 1,2,4a,5,6,8a-hexahydro-4,7-dimethyl-1-(1-methylethyl)-, (1S-(1alpha,4aalpha,8aalpha))-; C20272; Q27133436; (1S,4AS,8AR)-1,2,4A,5,6,8A-HEXAHYDRO-4,7-DIMETHYL-1-(1-METHYLETHYL)NAPHTHALENE; (1S,4aS,8aR)-4,7-dimethyl-1-propan-2-yl-1,2,4a,5,6,8a-hexahydronaphthalene
|
|
CAS | 10208-80-7 | |
PubChem CID | 12306047 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 4.1 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.524 |
Caco-2 Permeability: | -4.371 | MDCK Permeability: | 0.00001650 |
Pgp-inhibitor: | 0.023 | Pgp-substrate: | 0.021 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.991 |
30% Bioavailability (F30%): | 0.924 |
Blood-Brain-Barrier Penetration (BBB): | 0.326 | Plasma Protein Binding (PPB): | 95.04% |
Volume Distribution (VD): | 5.792 | Fu: | 3.65% |
CYP1A2-inhibitor: | 0.905 | CYP1A2-substrate: | 0.349 |
CYP2C19-inhibitor: | 0.563 | CYP2C19-substrate: | 0.841 |
CYP2C9-inhibitor: | 0.709 | CYP2C9-substrate: | 0.208 |
CYP2D6-inhibitor: | 0.045 | CYP2D6-substrate: | 0.155 |
CYP3A4-inhibitor: | 0.435 | CYP3A4-substrate: | 0.334 |
Clearance (CL): | 13.747 | Half-life (T1/2): | 0.077 |
hERG Blockers: | 0.103 | Human Hepatotoxicity (H-HT): | 0.351 |
Drug-inuced Liver Injury (DILI): | 0.501 | AMES Toxicity: | 0.061 |
Rat Oral Acute Toxicity: | 0.172 | Maximum Recommended Daily Dose: | 0.065 |
Skin Sensitization: | 0.556 | Carcinogencity: | 0.802 |
Eye Corrosion: | 0.734 | Eye Irritation: | 0.845 |
Respiratory Toxicity: | 0.567 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000831 | 1.000 | D04CSZ | 0.296 | ||||
ENC002223 | 1.000 | D0V2JK | 0.223 | ||||
ENC003093 | 0.585 | D0P1FO | 0.221 | ||||
ENC000800 | 0.577 | D0A2AJ | 0.213 | ||||
ENC002227 | 0.577 | D04GJN | 0.211 | ||||
ENC002017 | 0.474 | D0O1UZ | 0.209 | ||||
ENC001316 | 0.464 | D09PJX | 0.193 | ||||
ENC000762 | 0.458 | D06GIP | 0.186 | ||||
ENC000763 | 0.458 | D0K7LU | 0.184 | ||||
ENC001072 | 0.439 | D01CKY | 0.183 |